Skip to main content

Table 1 MIC of the proprietary RHB-104 capsule formulation and RHB-104 analog

From: A single capsule formulation of RHB-104 demonstrates higher anti-microbial growth potency for effective treatment of Crohn’s disease associated with Mycobacterium avium subspecies paratuberculosis

Microorganism Minimum inhibitory concentration (μg/mL)
CLA-CLO-RIF (RHB-104 analog)a Proprietary RHB-104 capsule formulationb
MAP MS 137 4.0 2.0
M. avium—JF7 4.0 2.0
M. fortuitum ss fortuitum 15 10
M. tuberculosis HR237 10 5.0
M. smegmatis ATCC 27199 6.0 0.125
S. aureus ATCC 25923 0.25 0.125
L. monocytogenes ATCC 19112 0.5 0.25
K. pneumonia ATCC 13883 >40 >40
Recombinant E. coli >40 >40
  1. All cultures were performed in duplicates and have been repeated three times
  2. aRHB-104 analog where the 3 drugs dissolved individually were combined in one solution at their proprietary RHB-104 capsule formulation composition percentage
  3. bProprietary RHB-104 capsule formulation was dissolved in one compatible solvent